[1] cancer-facts-and-figures-2021 https://www.cancer.org/content/dam/cancer-org/r
esearch/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer
-facts-and-figures-2021.pdf, (n.d.).
[2] A.M. Noone, K.A. Cronin, S.F. Altekruse, N. Howlader, D.R. Lewis, V.I. Petkov, L.
Penberthy, Cancer incidence and survival trends by subtype using data from the
surveillance epidemiology and end results program, 1992-2013, Cancer Epidemiol.
Biomarkers Prev. 26 (2017) 632–641. 10.1158/1055-9965.EPI-16-0520.
[3] V. Mittal, Epithelial mesenchymal transition in aggressive lung cancers, Adv. Exp.
Med. Biol. (2016) 37–56, https://doi.org/10.1007/978-3-319-24932-2_3.
[4] T. Sowa, T. Menju, M. Sonobe, T. Nakanishi, K. Shikuma, N. Imamura,
H. Motoyama, K. Hijiya, A. Aoyama, F. Chen, T. Sato, M. Kobayashi, A. Yoshizawa,
H. Haga, T. Sozu, H. Date, Association between epithelial-mesenchymal transition
and cancer stemness and their effect on the prognosis of lung adenocarcinoma,
Cancer Med. 4 (2015) 1853–1862, https://doi.org/10.1002/cam4.556.
[5] S. Neri, T. Menju, T. Sowa, Y. Yutaka, D. Nakajima, M. Hamaji, A. Ohsumi, T.
F. Chen-Yoshikawa, T. Sato, M. Sonobe, A. Yoshizawa, H. Haga, H. Date,
Prognostic impact of microscopic vessel invasion and visceral pleural invasion and
their correlations with epithelial–mesenchymal transition, cancer stemness, and
treatment failure in lung adenocarcinoma, Lung Cancer 128 (2019) 13–19, https://
doi.org/10.1016/j.lungcan.2018.12.001.
[6] S. Nishikawa, T. Menju, K. Takahashi, R. Miyata, T.F. Chen-Yoshikawa, M. Sonobe,
A. Yoshizawa, H. Sabe, T. Sato, H. Date, Statins may have double-edged effects in
patients with lung adenocarcinoma after lung resection, Cancer Manag. Res. 11
(2019) 3419–3432, https://doi.org/10.2147/CMAR.S200819.
[7] K. Takahashi, T. Menju, S. Nishikawa, R. Miyata, S. Tanaka, Y. Yutaka, Y. Yamada,
D. Nakajima, M. Hamaji, A. Ohsumi, T.F. Chen-Yoshikawa, T. Sato, M. Sonobe,
H. Date, Tranilast inhibits TGF-β1-induced epithelial-mesenchymal transition and
invasion/metastasis via the suppression of smad4 in human lung cancer cell lines,
Anticancer Res. 40 (2020) 3287–3296, https://doi.org/10.21873/
anticanres.14311.
[8] T. Menju, H. Date, Lung cancer and epithelial-mesenchymal transition, Gen.
Thorac. Cardiovasc. Surg. 69 (2021) 781–789, https://doi.org/10.1007/s11748021-01595-4.
[9] J. Xu, S. Lamouille, R. Derynck, TGF-В-induced epithelial to mesenchymal
transition, Cell Res. 19 (2009) 156–172, https://doi.org/10.1038/cr.2009.5.
[10] P. Papageorgis, T. Stylianopoulos, Role of TGFβ in regulation of the tumor
microenvironment and drug delivery (review), Int. J. Oncol. 46 (2015) 933–943,
https://doi.org/10.3892/ijo.2015.2816.
[11] J. Inglese, D.S. Auld, A. Jadhav, R.L. Johnson, A. Simeonov, A. Yasgar, W. Zheng,
C.P. Austin, Quantitative high-throughput screening: A titration-based approach
that efficiently identifies biological activities in large chemical libraries, Proc. Natl.
Acad. Sci. U. S. A. 103 (2006) 11473–11478, https://doi.org/10.1073/
pnas.0604348103.
[12] C.W. Hsu, R. Huang, T. Khuc, D. Shou, J. Bullock, S. Grooby, S. Griffin, C. Zou,
A. Little, H. Astley, M. Xia, Identification of approved and investigational drugs
that inhibit hypoxia-inducible factor-1 signaling, Oncotarget 7 (2016) 8172–8183,
https://doi.org/10.18632/oncotarget.6995.
[13] S. Lamouille, J. Xu, R. Derynck, Molecular mechanisms of epithelial-mesenchymal
transition, Nat. Rev. Mol. Cell Biol. 15 (2014) 178–196, https://doi.org/10.1038/
nrm3758.
[14] M.A. Nieto, R.Y.Y.J. Huang, R.A.A. Jackson, J.P.P. Thiery, EMT: 2016, Cell 166
(2016) 21–45, https://doi.org/10.1016/j.cell.2016.06.028.
[15] M.K. Wendt, T.M. Allington, W.P. Schiemann, Mechanisms of the epithelialmesenchymal transition by TGF-β, Future Oncol. 5 (2009) 1145–1168, https://doi.
org/10.2217/fon.09.90.
46
...
論文の公開元へ
